Aspirin resistance in secondary stroke prevention

Authors


Jörg Berrouschot, Department of Neurology, KKH Altenburg, Am Waldessaum 10, 04600 Altenburg, Germany
Tel.: +49-3447-521380
Fax: +49-3447-521397
e-mail: berrouschot.kkh-altenburg@t-online.de

Abstract

Background –  We investigated the platelet function in stroke patients treated with aspirin [acetylsalicylic acid (ASA)] for secondary stroke prevention during a follow-up period of 1 year.

Methods –  In this prospective study 291 patients with first initiated aspirin therapy (300 mg/day) for secondary stroke prevention were included. Platelet aggregation measurements were performed 24 h, 3, 6, and 12 months after starting medication.

Results –  Twenty-one of 291 patients (7.2%) were identified as primary ASA-non-responders (initial insufficient platelet inhibition) and 4.1% as secondary ASA-non-responders (insufficient platelet inhibition during follow-up). There were no significant differences between ASA-responders and ASA-non-responders concerning age, gender, risk factors, and stroke characteristics.

Conclusion –  Aspirin resistance in stroke patients is not uncommon. The clinical usefulness of routine platelet function tests needs to be proved by further trials.

Ancillary